The Column Group is a venture capital firm that focuses on building early-stage drug discovery companies based on unique scientific platforms and potential breakthrough therapeutics. Their strategy emphasizes long-term value generation by building fundamentally strong, science-driven companies from the ground up, primarily in the life sciences, including pharmaceuticals, biotechnology, and bioinformatics.
91% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Average disclosed round size is $97.5M (across 11 rounds with reported amounts).
Portfolio
11
Fund Size
$4.2B
Top Stage
Series B
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Atavistik Bio | Series B | $120M | Dec 2025 |
 Tr1X, Inc. | Series C | $50M | Oct 2025 |
 Surrozen, Inc. | Series D | $175M | Mar 2025 |
| RRAPT Therapeutics, Inc. | Series D | $150M | Dec 2024 |
| Tr1X, Inc. | Series A | $75M | Jan 2024 |
| KKimia Therapeutics, Inc. | Series A | $55M | Dec 2023 |
| CCarmot Therapeutics | Series E | $150M | May 2023 |
 Remix Therapeutics | Series A | $81M | Dec 2020 |
 A2 Biotherapeutics | Series B | $71.5M | Oct 2020 |
 Tenaya Therapeutics, Inc. | Series B | $92M | Oct 2019 |
| OORIC Pharmaceuticals | Series B | $53M | Dec 2015 |
Top Co-Investors
Alexandria Venture Investments3 shared
Casdin Capital2 shared
Foresite Capital2 shared
Nextech Invest2 shared
Samsara BioCapital2 shared
RA Capital Management2 shared
Deep Track Capital2 shared
OrbiMed2 shared
GV (Google Ventures)1 shared
Atlas Venture1 shared
ARCH Venture Partners1 shared
Lux Capital1 shared
Euclidean Capital1 shared
UC Investments1 shared
NEVA SGR1 shared
Dimension Capital1 shared
Horizon Ventures1 shared
Access Biotechnology1 shared
Vivo Capital1 shared
Last updated: 5 March 2026